This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0773 in healthy older men.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
68
Three 25mg oral tablets MK0773 bid, for 12 weeks
intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
placebo oral tablet bid, for 12 weeks
Number of subjects with Clinical Adverse Events (CAE)
Time frame: 12 weeks
Number of subjects with Serious CAEs
Time frame: 12 weeks
Number of subjects with drug-related CAEs
Time frame: 12 weeks
Number of subjects with serious drug-related CAEs
Time frame: 12 weeks
Number of subjects that discontinued with CAEs
Time frame: 12 weeks
Number of subjects with Laboratory Adverse Events (LAE)
Time frame: 12 weeks
Number of subjects with drug-related LAEs
Time frame: 12 weeks
Number of subjects with serious LAEs
Time frame: 12 weeks
Number of subjects with serious drug-related LAEs
Time frame: 12 weeks
Number of subjects that discontinued with LAEs
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
placebo intramuscular injection q14d, for 12 weeks